In contrast to hematologic malignancies, where lineage-specific markers such as CD19 and BCMA offer consistent targeting, many solid tumor-associated antigens (e.g., mesothelin, B7-H3, GPC3) are variably expressed and are not uniformly tumor-specific [6]. Here, MSLN is linked to hematologic disorder.